Antibody–drug conjugates (ADCs) is a fast moving class of targeted biotherapeutics that
currently combines the selectivity of monoclonal antibodies with the potency of a payload …

Efficacy and safety of chemotherapeutic drugs constitute two major criteria in tumor
chemotherapy. Nanomedicines with tumor‐targeted properties hold great promise for …

The active metabolite of irinotecan (CPT-11), 7-ethyl-10-hydroxycamptothecin (SN38), is
100–1000 times more active than CPT-11 and has shown inhibitory effects on a range of …

A co-delivery system of SN38 (7-ethyl-10-hydroxyl camptothecin) prodrug and CUR
(curcumin) was designed for the treatment of lung cancer by pulmonary delivery. SN38 was …

DNA topoisomerase I plays a key role in lubricating the wheels of DNA replication or RNA
transcription through breaking and reconnecting DNA single-strand. It is widely known that …

Kinesin family member 20A (KIF20A) is an essential regulator of cytokinesis. In this study, by
performing a retrospective study based on data from the Cancer Genome Atlas (TCGA) …

Irinotecan is used clinically for the treatment of colorectal cancer; however, its utility is limited
by its narrow therapeutic index. We describe the use of a generation 5 l-lysine dendrimer …

Due to the speed, efficiency, relative risk, and lower costs compared to traditional drug
discovery, the prioritization of candidate drugs for repurposing against cancers of interest …

Antibody drug-conjugates (ADCs) targeting human epidermal growth factor (HER2) are a
rapidly expanding class of cancer therapeutics. Such ADCs are known to suffer from …

Antibody–drug conjugates (ADCs) are a new class of targeted anti-cancer therapies that
combine a monoclonal tumor-surface-receptor-targeting antibody with a highly cytotoxic …